Volume 6 Issue 7 - November 21, 2008
Prof. Yonhua Tzeng
Breakthrough of Cancer Therapy by NCKU and NTU
Article Digest
Dong-Hwang Chen
Gum Arabic Modification and Glucose Grafting of Iron Oxide Nanoparticles as Novel Magnetic Nano-adsorbents
Chen-Kuei Chung
Effect of Microstructures on the Electrical and Optoelectronic Properties of Nanocrystalline Ta-Si-N Thin Films by Reactive Magnetron Cosputtering
KaoPing Chang
From Poems Inspired by Books to “Bi Xing” Metaphor: An Analysis of Lu You’s Du Shi Shi
Yea-Huei Kao Yang
Using the Claims Databases of National Health Insurance to Assess the Risk of Extrapyramidal Syndrome among Antipsychotics
Article Digest
Shui-Jinn Wang
Tin-based Metal Substrate Technology for the Fabrication of Vertical-Structure Gallium Nitride-Based Light-Emitting Diodes
News Release
Gratitude, Innovation, Advancing to Top 100 Universities—77th Anniversary of NCKU
NCKU Teams Won the First and Second Prizes of the “Taiwan Higher Education Intelligent Living Space Creativity Design Contest” Held by the Industrial Technology Research Institute
Editorial Group
Breakthrough of Cancer Therapy by NCKU and NTU
Prof. Yonhua Tzeng

Vice President for Research and Development

30th October 2008
A speech By Prof. Yonhua Tzeng

C ancer is the leading cause of death everywhere around the world, and now there is a breakthrough in treatment of this vicious disease. This drug, named “alpha-V-beta-3 disintegrin”, is a snake venom protein against integrin alpha-V-beta-3 (αVβ3)-related cancers. The use of venom protein for deadly disease is a milestone in the treatment of cancer. It is developed by the successful joint venture of National Cheng Kung University (NCKU) and National Taiwan University (NTU), the two leading comprehensive research universities in southern and northern Taiwan. Congratulations to them!

I want to thank the funding provided by the National Science and Technology Program for Biotechnology and Pharmaceuticals (NSTPBP), National Science Council (NSC). Prof. Woei-Jer Chuang, an expert on protein studies, in Institute of Biochemistry and Molecular Biology, College of Medicine, NCKU, used genetic engineering to take away harmful side effects of rhodostomin, and created a mutant protein eliminating thrombocytopenia effect. This protein was shown to work on treating metastatic bone cancer in animal experiment by Prof. Wen-Mei Fu, in Department of Pharmacology, NTU.

Dr. Chi-Ming Cheng, President of Anchen Pharmaceuticals (Taiwan) is pleased to sign the technology transfer of this drug with NCKU and NTU after vigorous evaluation. The signing ceremony is witnessed by Academician Wen-Chang Chang, Deputy Minister of National Science Council, Executive Yuan, and Dr. Che-Ming Teng, Head of NSTPBP on October 30th 2008. The agreement is signed by Inc, Prof. Yonhua Tzeng, Vice President for Research and Development, NCKU and Dr. Ji-Wang Chern, Vice President for Research and Development, NTU on behalf of Presidents Michael Ming-Chiao Lai and Si-Chen Lee, respectively. Except for paying a handsome amount of technology transfer fee to NCKU and NTU, it is estimated that a total sum of US$ 5 billion R & D fund will be invested in the coming five years. Together with NCKU and NTU, the research and development will continue. Hopefully this drug will pass clinical evaluation and be approved to benefit numerous cancer patients within five years. Potential worldwide annual sales is estimated to be up to NT$ 30 billion dollars (US$910 million dollars). A license fee in proportion to the annual sales will be rewarded to the two developers, NCKU and NTU.

Nine Colleges at NCKU, including Bioscience and Biotechnology, Liberal Arts, Sciences, Engineering, Electronic Engineering and Computer Science, Planning and Design, Management, Medicine, and Social Sciences, are adjacent to one another on the main campus, making cross disciplinary R&D possible. I want to thank the funding provided by National Science Council Projects and the Special Funding from 5Y50B Program by Ministry of Education. They boost the dynamics of our R&D facilities. This accomplishment is also made possible by the enormous supports from the academia and industry around the Southern Taiwan Science Park and 140,000 outstanding NCKU alumni in various lines worldwide.

Professors Chuang and Fu’s breakthrough have brought new vitality into the biotech pharmaceutical R&D teams in Taiwan. Today we witnessed the most successful case of Taiwan technology R&D with intellectual property protection. This case will serve as an outstanding model for university-industry collaboration, which will commercialize technology breakthrough in Taiwan with the help of an American pharmaceutical company. Let us congratulate Professors Chuang and Fu, and wish for the successful collaboration beween Anchen Pharmaceuticals (Taiwan) Inc, and the two professors to benefit human kind!
Copyright National Cheng Kung University